Suchergebnisse - "Addeo, A"

PubPharm (38)

1

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) : A Swiss cohort study

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Schuler, A. | Huser, J. | Schmid, S. | +16

2

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer : a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14

enthalten in: ESMO open | 2023

von König, D. | Savic Prince, S. | Hayoz, S. | +20

3

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era : results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455

enthalten in: ESMO open | 2022

von König, D. | Schär, S. | Vuong, D. | +19

ErratumFor: ESMO Open. 2022 Apr;7(2):100455. - PMID 35398718

4

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era : results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

enthalten in: ESMO open | 2022

von König, D. | Schär, S. | Vuong, D. | +19

ErratumIn: ESMO Open. 2022 Apr 22;7(3):100494. - PMID 35468561

5

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases : an exploratory analysis

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2021

von Metro, G. | Gili, A. | Signorelli, D. | +12

6

Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3) : a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078

enthalten in: ESMO open | 2021

von Banna, G. | Cortellini, A. | Cortinovis, D. | +43

ErratumFor: ESMO Open. 2021 Apr;6(2):100078. - PMID 33735802

7

The lung immuno-oncology prognostic score (LIPS-3) : a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

enthalten in: ESMO open | 2021

von Banna, G. | Cortellini, A. | Cortinovis, D. | +43

ErratumIn: ESMO Open. 2021 Jun;6(3):100137. - PMID 34144775

8

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis

enthalten in: Clinical and translational oncology | 2021

von Metro, G. | Gili, A. | Signorelli, D. | +12

9

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis

enthalten in: Clinical & translational oncology | 2021

von Metro, G. | Gili, A. | Signorelli, D. | +12

10

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis

enthalten in: Revista de oncología | 2021

von Metro, G. | Gili, A. | Signorelli, D. | +12